Sanofi’s ASH 2025: Redefining rare blood disorder care Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company's dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.

Sanofi’s #ASH25 data highlight leadership in rare blood diseases, from multi-immune modulation with #BTKinhibitor Wayrilz to long-term hemophilia care with ALTUVIIIO. Transforming patient lives through science.
#News #Interview #RareDisease #Hemophilia #Immunoscience

Sanofi’s ASH 2025: Redefining rare blood disorder care Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company's dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.

Sanofi’s #ASH25 data highlight leadership in rare blood diseases, from multi-immune modulation with #BTKinhibitor Wayrilz to long-term hemophilia care with ALTUVIIIO. Transforming patient lives through science.
#News #Interview #RareDisease #Hemophilia #Immunoscience